VIP (Vasoactive Intestinal Peptide): Research Overview

Key takeaways

• VIP is a 28-amino acid neuropeptide with research links to immune signaling, lung control, bone biology, eye biology, and exercise response.
• Recent studies point to roles in neuroimmune control of the lung, osteoprotective effects in human bone cell cultures, and reduced myopia progression in guinea pigs.
• Older and newer research both show VIP can shift inflammatory signaling, including findings in experimental arthritis and sarcoidosis-related work.
• Clinical lab testing for plasma VIP is used in the workup of VIP-secreting tumors, and sample handling is strict: chilled tubes, ice, and frozen transport.

Vasoactive Intestinal Peptide, or VIP, is a small signaling peptide with a wide research footprint. It appears in nervous system, immune, lung, bone, and eye research. It also has a place in clinical lab medicine, where plasma VIP can help support the diagnosis of VIP-secreting tumors. The current research picture is broad, but it is also mixed. Some findings come from human cell systems. Others come from animal studies, older experimental models, or clinical lab guidance. That makes VIP an important research target, but not a simple one.

What VIP is

VIP is a naturally occurring 28-amino acid neuropeptide. It acts as both a neurotransmitter and a hormone. In the research materials provided, it is described as a compound with effects that span immune function, circadian biology, and smooth muscle control. That breadth helps explain why VIP keeps showing up in different research fields.

In the lung, VIP sits within a larger neuroimmune network. A 2026 review on sensory neurons and lung immunity places VIP in the context of neuroimmune control of the lung. That matters because the lung is not only a breathing organ. It is also an immune interface. Signals from nerves can shape immune responses there, and VIP is part of that conversation.

VIP also appears in exercise physiology. In one PubMed study, plasma VIP increased during exercise lasting more than 20 minutes at a workload above 50% of VO2 max. The rise was even stronger after prolonged strain. In that study, glucose infusion during exercise almost abolished the increase. That is a concrete reminder that VIP can respond to changing body stress and fuel state, not just disease.

What current research says

Lung and neuroimmune signaling

The newest lung-focused review in the research bundle frames VIP as part of neuroimmune control in the lung. The review sits within a broader field looking at how sensory neurons shape immune activity in respiratory tissue. For VIP, that means the question is not just whether it dilates vessels or affects smooth muscle. It is also how it helps coordinate nerve-immune communication in the airways and lung environment.

That kind of role fits with VIP’s long-standing reputation as a regulatory peptide rather than a single-purpose molecule. In practical terms, the research field is moving toward systems thinking. VIP is being studied as one signal in a larger network, not as a lone actor.

Bone and skeletal tissue

A 2026 Translational Research paper reported osteoprotective effects of VIP in triple cultures of human osteocytes, osteoblasts, and osteoclasts. That is notable because these three cell types represent the core cellular players in bone remodeling. The study design suggests researchers are trying to understand how VIP affects the balance between bone formation and bone breakdown in a human-relevant model.

This is an important theme. VIP is not only being studied for inflammation. It is also being studied for tissue balance. Bone is a good example of that, because healthy bone depends on coordinated work across multiple cell types. A peptide that shifts that balance could matter in several disease settings, but the exact clinical meaning still needs more work.

Eye research and myopia

Another 2026 study reported that VIP attenuated form-deprivation myopia in guinea pigs by suppressing the Wnt/β-catenin pathway along the retina-choroid-scleral axis. That gives the research field a specific mechanistic clue. It also shows VIP being tested in a completely different organ system: the eye.

The study does not prove that VIP has the same effect in people. It does show that VIP can alter a signaling pathway tied to eye growth in an animal model. For researchers, that makes VIP part of a broader discussion about tissue signaling and growth control.

Immune and inflammatory research

VIP has a long research history in inflammation. A Johns Hopkins Arthritis summary of an experimental arthritis study reported that VIP delayed onset, lowered incidence, and reduced severity of collagen-induced arthritis in mice. The summary also described lower inflammatory infiltrate, less pannus formation, less cartilage destruction, and less bone erosion. Mechanistically, it reported reduced T-cell clonal expansion, lower Th1 cytokines, higher Th2 cytokines, suppression of type II collagen-specific IgG antibodies, and changes in inflammatory mediators such as tumor necrosis factor, interleukin-1, interleukin-10, and interleukin-1 receptor antagonist.

That is a dense list, but the core message is simple. In that animal model, VIP was associated with broad dampening of inflammatory and autoimmune features. The study is old, but it still matters because it helped define VIP as an immunomodulatory peptide.

The provided research also includes a PubMed item on osteoprotective effects and an older PubMed exercise study. Together, these sources support a general pattern: VIP is often studied where nerves, immune cells, and tissue responses overlap.

VIP in clinical testing and dose discussions

VIP has a clinical lab role that is separate from peptide research use. ARUP’s plasma VIP test is used to help diagnose VIP-secreting tumors, also called VIPomas. The lab guidance in the research bundle gives a reference interval of 0-89.1 pg/mL. It also gives strict collection instructions: collect in a prechilled EDTA tube, mix well, place on ice, transfer plasma, and freeze at -20. Acceptable transport and storage conditions are also listed, including frozen storage for up to 3 months after separation from cells.

That kind of detail matters because VIP is a fragile analyte. Testing only makes sense if the sample is handled correctly. For researchers and clinicians, the test guidance is part of the story because it shows how seriously pre-analytic conditions affect interpretation.

One 2026 dosing guide in the research bundle reports intranasal VIP doses ranging from 25-200 mcg and subcutaneous doses typically between 50-300 mcg. It also says most research protocols use 1-3 administrations daily. These figures are presented as guide-level dosing information, not as universal standards. The same source stresses that individual response varies and that storage and reconstitution matter. Because this is not a clinical guideline or a controlled trial, it should be treated as a reported dosing range rather than a recommendation.

What the older data add

The older material in the bundle helps place VIP in context. A PubMed exercise study showed that plasma VIP rises with sustained exercise and is affected by prolonged strain and glucose infusion. That tells us VIP is sensitive to physiological state. It is not just a static biomarker.

The Hopkins arthritis summary shows how VIP was already being studied decades ago for immune effects in animal disease models. That history is useful because it shows the current interest in VIP did not appear suddenly. The current papers on lung, bone, and eye biology are new branches of a longer research tree.

There is also a general theme across the bundle: VIP seems to be a mediator of coordination. It connects nerves to immunity, and it may also influence tissue remodeling. That does not mean it has the same effect in every system. It means the peptide is worth studying where different control systems overlap.

How to read the evidence

VIP research spans human cell systems, animal models, clinical lab testing, and older experimental work. That range is useful, but it also creates limits. A finding in mouse arthritis does not prove a human treatment effect. A guinea pig eye study does not prove a human eye effect. A culture study does not prove a whole-body effect. Each line of evidence answers a different question.

The strongest practical conclusion from the provided research is that VIP is a multi-role signaling peptide with clear activity in inflammation-linked biology. The newer studies extend that picture into lung neuroimmunity, bone cell balance, and myopia-related pathways. The clinical lab material shows that VIP also has a defined role in diagnosis when levels are being checked for VIP-secreting tumors.

If you are reading VIP research as a scientist, the main task is to separate mechanism from application. If you are reading it as a clinician or informed researcher, the main task is to distinguish validated lab use from experimental dosing ideas. The bundle supports both, but not equally.

FAQ

What is VIP?

VIP stands for Vasoactive Intestinal Peptide. In the research bundle, it is described as a 28-amino acid neuropeptide that works as both a neurotransmitter and a hormone.

What are the main research areas for VIP?

The provided studies cover lung neuroimmune control, bone cell biology, myopia research, inflammation, exercise physiology, and clinical testing for VIP-secreting tumors.

Does VIP have anti-inflammatory research support?

Yes. The arthritis summary describes reduced disease severity and lower inflammatory markers in a mouse model. The same theme appears in the broader research context, though the exact effects depend on the model and tissue.

What did the exercise study show?

It found that plasma VIP increased during exercise lasting more than 20 minutes at more than 50% of VO2 max, with an even stronger rise after prolonged strain. Glucose infusion during exercise almost abolished the increase.

How is plasma VIP tested clinically?

ARUP’s test guidance says VIP is measured in plasma, with a reference interval of 0-89.1 pg/mL. The sample must be collected in a prechilled EDTA tube, kept on ice, and frozen for transport.